Wa’el Hashad has been serving as the CEO of Longeveron, bringing with him more than 35 years of experience in the pharmaceutical and biotech industries. His therapeutic expertise includes cardiovascular, neuroscience, endocrine and inflammatory diseases. He is passionate about innovation and advancing science.

Prior to Longeveron, Hashad was the President and CEO of Avanir Pharmaceuticals where he led all aspects of the company’s commercial initiatives and the product development pipeline. He was the Chief Commercial Officer of Seres Therapeutics, where he spearheaded both strategy and development of various therapeutic types, including several microbiome-based therapies. He also held senior leadership positions at Amgen, Boehringer Ingelheim and Eli Lilly and Company.

Hashad holds a Bachelor of Science in Pharmacy from Cairo University and a Master of Business Administration from University of Akron.